Apollo University Of Cambridge Repositorymetadata only
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
32 biomedical and clinical sciences, 3201 cardiovascular medicine and haematology, 3202 clinical sciences, 3211 oncology and carcinogenesis, lymphoma, biotechnology, lymphatic research, genetics
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 214710
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.